FDA's complete response action on a cognitive function claim for Takeda Pharmaceutical Co. Ltd. and H. Lundbeck AS's antidepressant Brintellix could bode poorly for Acadia Pharmaceuticals Inc.'s Nuplazid, which is in a similar position of trying to gain approval based on a novel psychiatric endpoint.
Both drugs have received advisory committee support, but the March 29 complete response letter for Brintellix is a reminder that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?